Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $25.00 | Equal Weight → Overweight | Wells Fargo |
| 4/15/2025 | $18.00 | Neutral | Piper Sandler |
| 4/9/2025 | $16.00 | Buy → Neutral | UBS |
| 4/4/2025 | $40.00 → $17.00 | Overweight → Underweight | Analyst |
| 4/3/2025 | $36.00 → $22.00 | Buy → Underperform | BofA Securities |
| 12/20/2024 | $65.00 → $40.00 | Buy → Hold | Stifel |
| 12/11/2024 | $56.00 → $42.00 | Overweight → Equal Weight | Wells Fargo |
| 12/6/2024 | $52.00 | Buy | UBS |